AR059546A1 - Derivados de cromen -2-ona utiles como inhibidores de recaptacion del neurotransmisor de monoamina - Google Patents

Derivados de cromen -2-ona utiles como inhibidores de recaptacion del neurotransmisor de monoamina

Info

Publication number
AR059546A1
AR059546A1 ARP070100686A ARP070100686A AR059546A1 AR 059546 A1 AR059546 A1 AR 059546A1 AR P070100686 A ARP070100686 A AR P070100686A AR P070100686 A ARP070100686 A AR P070100686A AR 059546 A1 AR059546 A1 AR 059546A1
Authority
AR
Argentina
Prior art keywords
chromen
alkyl
group
inhibitors
useful
Prior art date
Application number
ARP070100686A
Other languages
English (en)
Original Assignee
Neurosearch As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Neurosearch As filed Critical Neurosearch As
Publication of AR059546A1 publication Critical patent/AR059546A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D451/00—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof
    • C07D451/02—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof
    • C07D451/04—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof with hetero atoms directly attached in position 3 of the 8-azabicyclo [3.2.1] octane or in position 7 of the 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring system
    • C07D451/06—Oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/46—8-Azabicyclo [3.2.1] octane; Derivatives thereof, e.g. atropine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Addiction (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Endocrinology (AREA)
  • Urology & Nephrology (AREA)
  • Epidemiology (AREA)
  • Reproductive Health (AREA)
  • Rheumatology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Dermatology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Vascular Medicine (AREA)
  • Psychology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Child & Adolescent Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Obesity (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Emergency Medicine (AREA)

Abstract

La presente se refiere a nuevos derivados de cromen-2-ona utiles como los inhibidores de la recaptacion del neurotransmisor de monoamina. Se refiere al uso de estos compuestos en un método para terapia y a composiciones farmacéuticas que comprenden los compuestos de de la presente. Reivindicacion 1: Un compuesto de formula 1 cualquiera de sus isomeros o cualquier mezcla de sus isomeros, o su sal aceptable para uso farmacéutico, donde Q representa un grupo cromen-2-ona; dicho grupo cromen-2- ona está opcionalmente sustituido con uno o más sustituyentes independientemente seleccionados del grupo integrado por: halo, trifluorometilo, trifluorometoxi, ciano, hidroxi, amino, nitro, alcoxi, cicloalcoxi, alquilo, cicloalquilo, cicloalquilalquilo, alquenilo y alquinilo; R1 representa hidrogeno o alquilo; dicho alquilo está opcionalmente sustituido con uno o más sustituyentes independientemente seleccionados del grupo integrado por: halo, trifluorometilo, trifluorometoxi, ciano, hidroxi, amino, nitro, alcoxi, cicloalcoxi, alquilo, cicloalquilo, cicloalquilalquilo, alquenilo y alquinilo; y R2 y R3 juntos forman -(CH2)-(CH2)- o -(CH)=(CH)-.
ARP070100686A 2006-02-17 2007-02-16 Derivados de cromen -2-ona utiles como inhibidores de recaptacion del neurotransmisor de monoamina AR059546A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DKPA200600233 2006-02-17

Publications (1)

Publication Number Publication Date
AR059546A1 true AR059546A1 (es) 2008-04-09

Family

ID=39272807

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP070100686A AR059546A1 (es) 2006-02-17 2007-02-16 Derivados de cromen -2-ona utiles como inhibidores de recaptacion del neurotransmisor de monoamina

Country Status (15)

Country Link
US (1) US8153797B2 (es)
EP (2) EP2311835A1 (es)
JP (1) JP2009526816A (es)
KR (1) KR20080096833A (es)
CN (1) CN101405287B (es)
AR (1) AR059546A1 (es)
AU (1) AU2007216535A1 (es)
BR (1) BRPI0707853A2 (es)
CA (1) CA2641916A1 (es)
IL (1) IL192485A0 (es)
NO (1) NO20083955L (es)
RU (1) RU2008129865A (es)
TW (1) TW200800980A (es)
WO (1) WO2007093604A1 (es)
ZA (1) ZA200805908B (es)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2007002384A (es) * 2004-09-30 2007-05-11 Neurosearch As Nuevos derivados de cromen-2-ona y su uso como inhibidores de la reabsorcion del neurotransmisor de monoamina.
MX2009005916A (es) * 2006-12-20 2009-06-19 Neurosearch As Nuevos derivados de cromen-2-ona y su uso como inhibidores de la reabsorcion del neurotransmisor de monoamina.
WO2008074797A1 (en) * 2006-12-20 2008-06-26 Neurosearch A/S Novel chromen-2-one derivatives and their use as monoamine neurotransmitter re-uptake inhibitors
RU2011143972A (ru) 2009-05-15 2013-06-20 НьюроСёрч А/С Производные хромен-2-она и их применение в качестве ингибиторов обратного захвата моноаминовых нейромедиаторов
US20130040985A1 (en) 2010-01-29 2013-02-14 Neurosearch A/S Chromen-2-one derivatives and their use as monoamine neurotransmitter re-uptake inhibitors
WO2011117289A1 (en) 2010-03-25 2011-09-29 Neurosearch A/S Chromen-2-one derivatives and their use as monoamine neuro-transmitter re-uptake inhibitors
WO2012000881A1 (en) 2010-07-02 2012-01-05 Neurosearch A/S Chromen-2-one derivatives and their use as monoamine neurotransmitter re-uptake inhibitors

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8923209D0 (en) * 1989-10-14 1989-11-29 Wyeth John & Brother Ltd Heterocyclic compounds
ATE224392T1 (de) 1995-11-02 2002-10-15 Neurosearch As Kondensierte tropanderivate als neurotransmitter- reuptake-inhibitoren
DE69705608T2 (de) * 1996-02-22 2002-05-16 Neurosearch A/S, Ballerup Tropanderivate, deren herstellung und verwendung
US5916914A (en) * 1997-08-08 1999-06-29 Warner-Lambert Company Compounds and method of treating psychosis and schizophrenia
EP1397358A1 (en) 2001-05-23 2004-03-17 Neurosearch A/S Tropane derivatives and their use as monoamine neurotransmitter re-uptake inhibitors
JP2005532368A (ja) 2002-06-12 2005-10-27 アボット・ラボラトリーズ メラニン濃縮ホルモン受容体の拮抗薬
US7538233B2 (en) 2003-09-05 2009-05-26 Aventis Pharmaceuticals Inc. Coumarins as iNOS inhibitors
ATE494286T1 (de) * 2004-09-30 2011-01-15 Neurosearch As Neue chromen-2-one derivate und ihre verwendung als monoamineneurotransmitter- wiederaufnahmeinhibitoren
CA2591621A1 (en) 2004-12-17 2006-06-22 Neurosearch A/S Enantiomers of 3-heteroaryl-8h-8-azabicyclo(3.2.1)oct-2-ene and their use as monoamine neurotransmitter re-uptake inhibitors
MX2009005916A (es) 2006-12-20 2009-06-19 Neurosearch As Nuevos derivados de cromen-2-ona y su uso como inhibidores de la reabsorcion del neurotransmisor de monoamina.
WO2008074797A1 (en) 2006-12-20 2008-06-26 Neurosearch A/S Novel chromen-2-one derivatives and their use as monoamine neurotransmitter re-uptake inhibitors

Also Published As

Publication number Publication date
CN101405287A (zh) 2009-04-08
JP2009526816A (ja) 2009-07-23
ZA200805908B (en) 2009-10-28
EP1989202A1 (en) 2008-11-12
NO20083955L (no) 2008-09-16
CA2641916A1 (en) 2007-08-23
RU2008129865A (ru) 2010-03-27
TW200800980A (en) 2008-01-01
KR20080096833A (ko) 2008-11-03
AU2007216535A1 (en) 2007-08-23
EP1989202B1 (en) 2012-07-25
IL192485A0 (en) 2009-02-11
WO2007093604A1 (en) 2007-08-23
US8153797B2 (en) 2012-04-10
CN101405287B (zh) 2011-05-18
EP2311835A1 (en) 2011-04-20
BRPI0707853A2 (pt) 2011-05-10
US20100227883A1 (en) 2010-09-09

Similar Documents

Publication Publication Date Title
CO5630004A2 (es) Derivados novedosos del 8-aza-biciclo [3,2,1] octano y su uso como inhibidores de la re-captacion de neurotransmisores monoaminicos
AR059546A1 (es) Derivados de cromen -2-ona utiles como inhibidores de recaptacion del neurotransmisor de monoamina
ECSP066784A (es) 5,6 dialquil-7 -amino-triazolopirimidinas, procedimientos para su preparacion y el uso de las mismas para combatir hongos nocivos, asi como productos que las contienen
CL2012000999A1 (es) Compuestos derivados de pirazoloespirocetona sustituida, inhibidores de acetil-coa carboxilasa; composicion farmaceutica que los comprende; uso para tratar o retrasar la progresion o el inicio de diabetes tipo 2, higado graso no alcoholico (hgna) o la resistencia hepatica a la insulina.
AR050341A1 (es) Compuestos derivados de piperidina, composicion farmaceutica en base al compuesto y su uso para preparar medicamentos
CO6260076A2 (es) Derivados de uracilo o timina para el tratamiento de la hepatitis c
ECSP066829A (es) 5,6 dialquil-7 -amino-triazolopirimidinas, procedimientos para su preparacion y el uso de las mismas para combatir hongos nocivos
UY29886A1 (es) Derivados de pirazol novedosos, composiciones farmaccuticas que los contienen, procedimientos para la preparacinn de los mismos y aplicaciones
UY29393A1 (es) Nuevos derivados de amidas, sales farmacéuticas aceptables, composiciones que los contienen, procedimientos de preparación y aplicaciones.
CR20110484A (es) Nuevos derivados de benzotiazepinas su procedimiento de preparacion y composiciones farmaceuticas que los contienen
BRPI0507495A (pt) composto, composição farmacêutica, uso do composto método para o tratamento de distúrbios mediados por mglur5, e, método para inibir a ativação de receptores de mglur5
PA8660401A1 (es) Derivados de triazol sustituidos como antagonistas de oxitocina
CU20090048A7 (es) Nuevos derivados de diosmetina, su procedimiento de preparación y las composiciones farmacéuticas que los contienen
AR049577A1 (es) Derivados de hidantoina, procesos para su preparacion, composiciones y su uso
UY29070A1 (es) Enantiómeros de heterocíclicos fusionados y sus usos
CO6251235A2 (es) Compuestos derivados de azetidinas su preparacion y su aplicacion en terapeutica
ECSP099351A (es) Compuestos heterociclicos y su uso como inhibidores de la
PE20091359A1 (es) Proceso de preparacion de compuestos organicos intermediarios de inhibidores de renina
AR073043A1 (es) Compuestos de azetidinas polisustituidos, composiciones farmaceuticas que los contienen, metodo de preparacion y uso de los mismos en el tratamiento de enfermedades respiratorias, metabolicas y del sistema nervioso central, entre otras.
ECSP088257A (es) Derivados de amida
AR069607A1 (es) Inhibidores de la estearoil-coa desaturasa
AR064457A1 (es) Derivados de 7-[(8-aza-biciclo[3,2,1]oct-3-il)-oxi]-3-heteroaril-2-il-cromen-2-ona una composicion farmaceutica que los comprende y su uso para la elaboracion de un medicamento para el tratamiento de una enfermedad mediada por la ssri
AR049923A1 (es) Derivados de piperidina sustituidos
AR074413A1 (es) Derivados de 2-morfolino-3-amido-piridina
AR056804A1 (es) Derivados de 8-aza-biciclo(3.2.1)octano de utilidad como inhibidores de la recaptacion del neurotransmisor monoamina

Legal Events

Date Code Title Description
FA Abandonment or withdrawal